Celyad Oncology S.A (CYAD) | Stock Overview & Key Data
Celyad Oncology S.A. | Small-cap | Healthcare
Celyad Oncology S.A. | Small-cap | Healthcare
Celyad Oncology S.A Performance Comparison
Stock Range
Today's Range
Low: €0.37
High: €0.39
on August 8, 2025
52 Week Range
Low: €0.21
High: €1.22
on August 20, 2024
on November 7, 2024
All-Time High: €70.95 on May 18, 2015
Explore how other BE stocks compare to their 52-week ranges: View BE Market 52-Week Insights
Key Statistics
Market Cap
€16.2M
EPS
-1.36
P/E Ratio (TTM)
-0.22
Forward P/E
0.61
P/B Ratio
32.50
PEG Ratio
0.61
Div. Yield
N/A
ROE
-170.92%
Beta
1.051
Debt to Equity
177.10
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-1,619.77%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-28.00%
Return on Equity (TTM)
-170.92%
EBITDA
€-5.7M
Net Income (TTM)
€-5.8M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.01
Quarterly Revenue Growth (YoY)
196.60%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Celyad Oncology S.A CYAD | 16.16M Small-cap | -2.50% | 11.43% | -17.02% | -9.30% | -41.79% | 69.57% | -80.98% | -95.52% |
| Argenx SE ARGX | 36.23B Large-cap | -3.13% | 23.59% | 5.46% | -8.89% | -5.73% | 18.28% | 57.28% | 191.69% |
| UCB S.A UCB | 35.08B Large-cap | -3.12% | 8.59% | 17.93% | -2.51% | -3.58% | 15.99% | 149.93% | 78.52% |
| European Medical ALEMS | 19.47M Small-cap | -2.13% | 4.55% | -16.36% | -26.98% | -23.33% | -37.75% | -89.95% | -92.27% |
| Biosenic SA BIOS | 1.63M Small-cap | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -80.00% | -98.25% | -99.73% |
| Oxurion NV OXUR | 1.52M Small-cap | 0.00% | 0.00% | -57.14% | -87.50% | -88.00% | -97.00% | -100.00% | -100.00% |
Ownership & Short Interest
Insider Ownership
10.67%
Institutional Ownership
55.34%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
89K
Average 90-Day Volume
39K
Celyad Oncology S.A Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Celyad Oncology S.A would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is CYAD's 52-week high and low?
- In the last 52 weeks, Celyad Oncology S.A reached a high of €1.22 (on November 7, 2024) and a low of €0.21 (on August 20, 2024).
- What is the market cap and P/E ratio for CYAD?
- Curious about Celyad Oncology S.A's size and valuation? Its market capitalization stands at 16.16M. When it comes to valuation, the P/E ratio (trailing twelve months) is -0.22, and the forward P/E (looking ahead) is 0.61.
- Does CYAD pay dividends? If so, what's the yield?
- As for dividends, Celyad Oncology S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Celyad Oncology S.A's main competitors or similar companies to consider before investing?
When looking at Celyad Oncology S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Argenx SE
ARGX36.23B Healthcare Biotechnology 18.28% 57.28% UCB S.A
UCB35.08B Healthcare Biotechnology 15.99% 149.93% European Medical
ALEMS19.47M Healthcare Biotechnology -37.75% -89.95% Biosenic SA
BIOS1.63M Healthcare Biotechnology -80.00% -98.25% Oxurion NV
OXUR1.52M Healthcare Biotechnology -97.00% -100.00% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Celyad Oncology S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Celyad Oncology S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -170.92%, the Debt to Equity ratio from the most recent quarter is 177.10, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for CYAD?
- Looking at Celyad Oncology S.A's growth, its revenue over the trailing twelve months (TTM) was €186K. Compared to the same quarter last year (YoY), quarterly revenue grew by 196.60%, and quarterly earnings saw a YoY growth of N/A.
- How much of CYAD stock is held by insiders and institutions?
- Wondering who owns Celyad Oncology S.A stock? Company insiders (like executives and directors) hold about 10.67% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 55.34%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.